



2012 PROGRAM AT-A-GLANCE

19th Conference on Retroviruses and Opportunistic Infections

Time	DAY 1	DAY 2	DAY 3	DAY 4
	Mon, March 5, 2012	Tue, March 6, 2012	Wed, March 7, 2012	Thu, March 8, 2012
8:30-9 am		Plenary ART for Prevention: The Science and the Art Wafaa El-Sadr	Plenary Elimination of Mother-to-Child Transmission of HIV Dorothy Mbori-Ngacha	Plenary From the Cage to the Clinic: Developing TB Regimens for the Next 40 Years Eric Nuermberger
9-9:30 am	Program Committee Workshop for New Investigators and Trainees featuring the Martin Delaney Lecture: Community Responses to PrEP and Treatment as Prevention Nikos Dedes	Plenary Arms and the Virus: Evolution of HIV, SIV, and their Hosts Michael Emerman	Plenary Structure and Function of the HIV-1 Envelope Glycoproteins Joseph Sodroski	Plenary AIDS and the Global Burden of Disease Christopher Murray
9:30-10 am		<i>Break</i>	<i>Break</i>	<i>Break</i>
10 am-12 n		Oral Abstracts Critical Treatment Issues in Women and Children HIV Prevention: PrEP, Microbicides, and Circumcision HIV-Host Interplay: The Immune and Cellular Response Breakthroughs in Hepatitis	Oral Abstracts Neurological Issues in HIV Infection: Natural History, Markers, and Treatment Treatment in Resource Limited Settings: Impact and Challenges Advances in Vaccines and IBTs State of the "ART" and Drug Resistance	Oral Abstracts Cancer and HIV: Treatment, Pathogenesis, and Risk Factors Epidemiology: Lives Saved and Persons at Risk TB and Vaccine Preventable Diseases HIV Persistence, Latency, and Eradication
12 n-1 pm		<i>Lunch</i>	<i>Lunch</i>	<i>Lunch</i>
1-2 pm		Themed Discussions Biomarkers of Inflammation in Pregnant and Nonpregnant Women Complications of HIV and ART in Children and Adolescents Pharmacogenomics of Drug Toxicity Restriction Factors and Virus-Host Coevolution Cryptococcal Meningitis: Advances in Diagnosis and Management Predicting Hepatitis C Treatment Responses	Themed Discussions Aging and Neurocognitive Impairment Elite Controllers Novel Approaches to Testing and Linkage to Care Pharmacometrics: Drug Exposure and Response Modelling Correlates of Risk in RV144 and Related Trials Animal and Human Studies of PrEP and Vaginal Rings	Themed Discussions Molecular Epidemiology: Primate Viruses and How They Affect Humans HIV-associated Malignancies: Emerging Themes in Epidemiology Complexities of ART for Pregnant and Postpartum Women TB Diagnostics Biomarkers and Complications: Associations and ART Effects Breaking Latency
2-4 pm	<i>Break</i>	Poster Abstracts <i>see page 2 for listings</i>	Poster Abstracts <i>see page 2 for listings</i>	Poster Abstracts <i>see page 2 for listings</i>
4-6 pm	Frontiers in Laboratory Science Workshop	Oral Abstracts Host and Viral Factors in HIV Transmission	Oral Abstracts Metabolic and Cardiovascular Complications	Oral Abstracts HIV/SIV Host Interactions
	Clinical Trials Design Workshop	Symposia Host Cell Factors Influencing HIV Replication Next Steps in Using ARVs for Prevention Hepatitis: Discovery in Practice	Symposia Pathways toward a Cure: Viral Latency and Reservoirs Recognizing Risk in HIV-Exposed and Infected Infants New Frontiers in HIV Testing	Symposia Ontogeny of a Protective Immune Response to HIV Scientific Advances in TB Pathogenesis and Treatment The Long and Winding Road of HIV Complications
6-7 pm	<i>Break</i>			
7-9 pm	Opening Session 17 th Bernard Fields Award Lecture Defying the Structure and Variability of HIV with Broadly Neutralizing Antibodies Dennis Burton 6 th N'Galy-Mann Award Lecture CAPRISA: Partnering for Scientific Innovation in HIV Prevention and Treatment Quarraisha and Salim Abdool Karim			
	Welcome Reception			

2-4 pm	Tue, March 6, 2012	Wed, March 7, 2012	Thu, March 8, 2012
	<p>Cellular Factors in Viral Replication and Novel Therapeutic Targets</p> <p>New Tools for Analysis of Viral Replication</p> <p>Impact of GBV and HSV on HIV</p> <p>HIV-Macrophage Interplay</p> <p>Viral Characteristics Linked to Pathogenicity</p> <p>Immune Activation: Contributing Factors and Impact on Progression</p> <p>Viral Persistence on Therapy</p> <p>Viral Replication off Therapy</p> <p>Coordinated Immune Responses</p> <p>Factors Associated with HIV Resistance</p> <p>Correlates of Risk in RV144 and Related Trials</p> <p>Post-Hoc Assessment of Vaccine Trials</p> <p>Neuropathogenesis Virology: HIV and SIV</p> <p>Neuropathogenesis: Early Infection Markers, CNS Inflammation</p> <p>Phylogeny and Relationship to Transmission, Pathogenicity and HLA Profile</p> <p>Genetics and Phylogenetics of HIV Transmission</p> <p>Compartment and Sanctuary Site Pharmacology</p> <p>Pharmacometrics: Drug Exposure and Response Modeling</p> <p>HIV Diagnostics: Nucleic Acid Detection, Sequencing and Dried Blood Spots</p> <p>Mechanisms of Antiviral Drug Resistance</p> <p>Resistance to 2nd Generation NNRTIs</p> <p>HCV Epidemiology and Natural History</p> <p>Cure of a Chronic Viral Infection</p> <p>Genes and Drugs: Pharmacogenetics of HCV Treatment</p> <p>Biomarkers and Complications: Associations and ART Effects</p> <p>Inflammatory Biomarkers, Immune Activation and ART</p> <p>Abacavir and Inflammation</p> <p>Fat: Changes on ART and Pathogenesis</p> <p>Dyslipidemia</p> <p>Glucose, Insulin Resistance and Testosterone</p> <p>Strategies for TB Screening: Prevention, Diagnosis and Reduced Transmission</p> <p>TB Diagnostics</p> <p>ART Strategies and Outcomes among Children</p> <p>Cardiovascular Complications in Children and Adolescents</p> <p>Response to Protective Vaccines</p> <p>Host and Immune Factors in Pediatric HIV Infection</p> <p>PMTCT: Retention in Care and Adherence during and after Pregnancy</p> <p>Point of Care: CD4 in Pregnancy</p> <p>PMTCT: Infant Feeding Recommendations and Practices</p> <p>Complexities of ART for Pregnant and Postpartum Women</p> <p>ART Immune Status and Viral Suppression during Pregnancy</p> <p>Women and HIV: Access to Care and Sexual Power Dynamics</p> <p>HIV Prevention Trials: HIV Test Performance, Pregnancy, Bone Toxicity and Resistance</p> <p>Preclinical Studies of Microbicides</p> <p>Animal and Human Studies of PrEP and Vaginal Rings</p> <p>Risk Behaviors</p> <p>Transmission Networks</p> <p>Linkage, Adherence, and Retention in Care</p>	<p>Envelope, Receptors and Virus Binding to Target Cells, Autophagy</p> <p>Restriction Factors and Virus-Host Co-Evolution</p> <p>Host Resistance to Infection and Disease Progression</p> <p>Impact of HIV on Immune Cell Function and Reservoir Studies</p> <p>HIV and T Cell Exhaustion</p> <p>Unconventional Reservoirs</p> <p>Breaking Latency</p> <p>CTL Escape Pathways</p> <p>CTL and Viral Control in vivo</p> <p>CTL and Viral Suppression in vitro</p> <p>Novel Vaccine Strategies</p> <p>Novel Gene Therapy Approaches</p> <p>HAND Predictors and Comorbidities</p> <p>HIV-associated Neuropathies</p> <p>HAND Therapies and CNS Penetration</p> <p>Molecular Epidemiology: Primate Viruses and How They Affect Humans</p> <p>Acute/Primary HIV Infection</p> <p>HIV Diagnostics: Acute and Recent Infection</p> <p>New ARV Agents and Approaches</p> <p>Pharmacokinetics, Dynamics, Adverse Reactions and Complications</p> <p>ART: Initiation and Outcomes</p> <p>Treatment Initiation</p> <p>Improving Treatment Outcome</p> <p>HIV Diagnostics: Point of Care and Mobile CD4 Testing</p> <p>Transmitted ARV Drug Resistance in Developed Countries</p> <p>Prevalence of Darunavir Resistance in Developing Countries</p> <p>Predicting Hepatitis C Treatment Responses</p> <p>The Next Frontier: HCV Resistance</p> <p>ART, Insulin Resistance, and the Liver</p> <p>Cardiovascular and Pulmonary Disease: Risk Factors and Predictors of Progression</p> <p>Stroke, Myocardial Infarction and Sudden Death</p> <p>Role of HIV</p> <p>Interventions to Reduce Cardiovascular Disease</p> <p>Sexually Transmitted Infections and Dysplasia</p> <p>HIV-associated Malignancies: Emerging Themes in Epidemiology</p> <p>HIV-associated Malignancies: Update in Treatment and Pathogenesis</p> <p>TB Risk, Outcomes and Impact of ART on TB Treatment</p> <p>TB Drug Resistance</p> <p>Immune Reconstitution Inflammatory Syndromes and Pathogenic Specific Immunity</p> <p>Early Infant HIV Diagnosis</p> <p>Retention and Adherence in Children and Adolescents</p> <p>Treatment Outcomes and Complications in HIV+ Adolescents</p> <p>ARV Pharmacokinetics and Pharmacogenetics in Children</p> <p>Estimates of New Pediatric Infections and PMTCT Program Outcomes</p> <p>Pregnancy Complications among HIV+ Women</p> <p>PMTCT: Child Health Outcomes</p> <p>Long Term Outcomes of ART Exposure for PMTCT</p> <p>Biomarkers of Inflammation in Pregnant and Non-Pregnant Women</p> <p>Estimating Incidence</p> <p>Engagement in Care</p> <p>Community Viral Load</p> <p>Disease Progression and Mortality</p>	<p>Antiviral Restrictions: Insight into Mechanisms of Action</p> <p>Studies on Viral Capsid and Assembly</p> <p>Virus Evolution, Fitness and Splicing</p> <p>Studies on Antigen Presenting Cell Changes in HIV Infection</p> <p>Impact of Treatment on Different Cell Subsets</p> <p>Elite Controllers</p> <p>HIV Reservoir: Immunologic Markers and Interventions</p> <p>in vitro Models of Latency</p> <p>Evolution of the Neutralizing Antibody Response in vivo</p> <p>Novel Methods for Detecting and Evaluating Neutralizing Antibodies</p> <p>Neutralizing Antibodies: Application to Vaccines and Therapies</p> <p>Therapeutic Vaccines and Immune Based Therapies</p> <p>Aging and Neurocognitive Impairment</p> <p>Clinical Evaluation of Neurocognitive and Neuropsychiatric Dysfunction</p> <p>Neuroimaging Studies of HAND</p> <p>Methods for Phylogenetic and Population Analysis of HIV</p> <p>Mechanism of Genital HIV Transmission</p> <p>Pharmacogenomics of Drug Toxicity</p> <p>Drug Interactions</p> <p>ART: Randomized Trials</p> <p>Disparities and Linkage to Care</p> <p>Plasma HIV RNA in HIV-1 and HIV-2 Infection</p> <p>Drug Resistance Evolution</p> <p>Resistance to Entry Inhibitors</p> <p>ARV Resistance and Therapy Outcome</p> <p>Immunopathogenesis of Hepatitis</p> <p>Hepatitis B and E around the World</p> <p>Frailty and Muscle Mass: Measures, Predictors and Outcomes</p> <p>Estimating Creatinine Clearance: Are We There Yet?</p> <p>Renal Disease: Association with Long Term Outcomes</p> <p>Low Bone Density: Etiology, Associations and Role of ART</p> <p>Vitamin D Deficiency: Let the Sun Shine In</p> <p>Hepatic and Gastrointestinal Complications</p> <p>Bacterial and Non-Tuberculosis Mycobacterial Infections</p> <p>Cryptococcal Meningitis: Advances in Diagnosis and Management</p> <p>Response to ART and Comorbidities in Infants and Children</p> <p>Complication of HIV and ART in Children and Adolescents</p> <p>HIV Drug Resistance and Tropism (after Treatment Failure) in Children</p> <p>TB Diagnosis and Treatment in Children</p> <p>ARV Regimens and Prevention of MTCT</p> <p>ART Pharmacokinetics during Pregnancy</p> <p>Neutralizing Antibodies and MTCT</p> <p>Immune Factors Associated with Immune Activation and MTCT</p> <p>Women and HIV: Structural Factors, Contraceptives and Mucosal Integrity</p> <p>HIV Prevention: PrEP, Circumcision and Population Viral Load</p> <p>Modelling the Impact of Prevention Strategies</p> <p>Novel Approaches to Testing and Linkage to Care</p> <p>Testing and Prevention</p> <p>HIV Testing and Disclosure</p>